YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA mo...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.709548/full |
id |
doaj-6d5cecdcb4ad45769a32d278a6364d80 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ganglin Su Ganglin Su Ganglin Su Ganglin Su Tianshu Liu Xiaohong Han Hao Sun Hao Sun Hao Sun Wenan Che Kun Hu Kun Hu Kun Hu Junwen Xiao Junwen Xiao Junwen Xiao Yanfeng Li Yanfeng Li Yanfeng Li Yuchen Liu Yuchen Liu Yuchen Liu Wujiao Li Wujiao Li Hongbing Mei Hongbing Mei Hongbing Mei |
spellingShingle |
Ganglin Su Ganglin Su Ganglin Su Ganglin Su Tianshu Liu Xiaohong Han Hao Sun Hao Sun Hao Sun Wenan Che Kun Hu Kun Hu Kun Hu Junwen Xiao Junwen Xiao Junwen Xiao Yanfeng Li Yanfeng Li Yanfeng Li Yuchen Liu Yuchen Liu Yuchen Liu Wujiao Li Wujiao Li Hongbing Mei Hongbing Mei Hongbing Mei YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma Frontiers in Pharmacology YTHDF2 KIRC biomarker prognosis immune infiltrates N6-methyladenosine (m6A) RNA methylation |
author_facet |
Ganglin Su Ganglin Su Ganglin Su Ganglin Su Tianshu Liu Xiaohong Han Hao Sun Hao Sun Hao Sun Wenan Che Kun Hu Kun Hu Kun Hu Junwen Xiao Junwen Xiao Junwen Xiao Yanfeng Li Yanfeng Li Yanfeng Li Yuchen Liu Yuchen Liu Yuchen Liu Wujiao Li Wujiao Li Hongbing Mei Hongbing Mei Hongbing Mei |
author_sort |
Ganglin Su |
title |
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma |
title_short |
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma |
title_full |
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma |
title_fullStr |
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma |
title_full_unstemmed |
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma |
title_sort |
ythdf2 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-08-01 |
description |
Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of “mRNA surveillance pathway,” “RNA degradation,” and “RNA transport” in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC. |
topic |
YTHDF2 KIRC biomarker prognosis immune infiltrates N6-methyladenosine (m6A) RNA methylation |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.709548/full |
work_keys_str_mv |
AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT tianshuliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT xiaohonghan ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT haosun ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT haosun ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT haosun ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT wenanche ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT kunhu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT kunhu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT kunhu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT junwenxiao ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT junwenxiao ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT junwenxiao ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT yanfengli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT yanfengli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT yanfengli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT yuchenliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT yuchenliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT yuchenliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT wujiaoli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT wujiaoli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT hongbingmei ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT hongbingmei ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma AT hongbingmei ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma |
_version_ |
1717817334472638464 |
spelling |
doaj-6d5cecdcb4ad45769a32d278a6364d802021-09-03T11:45:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-08-011210.3389/fphar.2021.709548709548YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell CarcinomaGanglin Su0Ganglin Su1Ganglin Su2Ganglin Su3Tianshu Liu4Xiaohong Han5Hao Sun6Hao Sun7Hao Sun8Wenan Che9Kun Hu10Kun Hu11Kun Hu12Junwen Xiao13Junwen Xiao14Junwen Xiao15Yanfeng Li16Yanfeng Li17Yanfeng Li18Yuchen Liu19Yuchen Liu20Yuchen Liu21Wujiao Li22Wujiao Li23Hongbing Mei24Hongbing Mei25Hongbing Mei26Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaShantou University Medical College, Shantou, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaHunan Key Laboratory of Economic Crops Genetic Improvement and Integrated Utilization, School of Life Sciences, Hunan University of Science and Technology, Xiangtan, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaClear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of “mRNA surveillance pathway,” “RNA degradation,” and “RNA transport” in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.https://www.frontiersin.org/articles/10.3389/fphar.2021.709548/fullYTHDF2KIRCbiomarkerprognosisimmune infiltratesN6-methyladenosine (m6A) RNA methylation |